ProCE Banner Activity

Applying New European Guideline Updates in AML: Experts Review Current Best Practice in Treatment and Molecular Testing―Madrid

Multimedia
Learn more about the latest guideline updates on AML and how those changes are poised to impact practice in this webcast from the second of 2 expert roundtables.

Released: December 01, 2022

Expiration: November 30, 2023

Share

Faculty

Claudio Cerchione

Claudio Cerchione, MD, PhD

Romagnolo Institute for the Study of Tumors "Dino Amadori"
Hematology Unit
Medical Director/Researcher
Hematology Unit
Istituto Romagnolo per Lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
Meldola, Italy

Naval G. Daver

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Pau Montesinos

Pau Montesinos, MD, PhD

Professor
Department of Hematology
Hospital La Fe
Valencia, Spain

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Adolfo de la Fuente Burguera

Adolfo de la Fuente Burguera, MD

Head of Hematology Department
MD Anderson CC Madrid
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Servier Pharmaceuticals

Program Director Disclosure

Program Director

Adolfo de la Fuente Burguera, MD

Head of Hematology Department
MD Anderson CC Madrid
Madrid, Spain

Adolfo de la Fuente Burguera, MD: speaker: AbbVie, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Incyte, Janssen-Cilag, Jazz, Novartis, Pfizer, Roche; advisor: AbbVie, Astellas, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Incyte, Jazz, Mundipharma, Pfizer, Roche; researcher: BTG, Janssen-Cilag, Novartis.

Faculty Disclosure

Primary Author

Claudio Cerchione, MD, PhD

Romagnolo Institute for the Study of Tumors "Dino Amadori"
Hematology Unit
Medical Director/Researcher
Hematology Unit
Istituto Romagnolo per Lo Studio dei Tumori "Dino Amadori" - IRST IRCCS
Meldola, Italy

Claudio Cerchione, MD, PhD: consultant/advisor/speaker: Glycomimetics, Menarini/Stemline.

Naval G. Daver, MD

Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval G. Daver, MD: researcher: AbbVie, Amgen, Astellas, Bristol-Myers Squibb, Daiichi Sankyo, FATE Therapeutics, Genentech, Gilead, Glycomimetics, Hanmi, ImmunoGen, Novimmune, Pfizer, Servier, Trillium, Trovagene; consultant/advisor/speaker: AbbVie, Agios, Astellas, Amgen, Arog, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Gilead, Jazz, Novartis, Pfizer, Servier, Shattuck Labs, Syndax, Trillium; independent contractor: ImmunoGen.

Pau Montesinos, MD, PhD

Professor
Department of Hematology
Hospital La Fe
Valencia, Spain

Pau Montesinos, MD, PhD, has no relevant financial relationships to disclose.

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: AbbVie, Agios, Aptose, Astellas, Blueprint, Bristol Myers Squibb, Calithera, CTI Biopharma, Daiichi Sankyo, Foghorn, Genentech, Genesis, Gilead, Janssen, Jazz Pharmaceuticals, Kura, Menarini, Neoleukin, Novartis, OnCusp, Ono Pharma, PinotBio, Servier, Syndax, Syros; data and safety monitoring board: Cellectis, Epizyme; researcher: Bristol Myers Squibb, Eisai; stock/stock options: Auron.